Enanta Pharmaceuticals Reports Q2 2025 Financial Results

Enanta Pharmaceuticals ( (ENTA) ) has released its Q2 earnings. Here is a breakdown of the information Enanta Pharmaceuticals presented to its investors.

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases, with a strong emphasis on respiratory syncytial virus (RSV) and type 2 inflammation.

In its fiscal second quarter ending March 31, 2025, Enanta Pharmaceuticals reported a net loss of $22.6 million, a decrease from the previous year’s loss of $31.2 million, while achieving significant milestones in its drug development pipeline. The company successfully met its target enrollment for a Phase 2 study of zelicapavir in high-risk adults with RSV and is progressing with its STAT6 and KIT inhibitor programs in immunology.

Key financial highlights include total revenue of $14.9 million, primarily from royalties on AbbVie’s hepatitis C virus regimen, and a strengthened cash position of $193.4 million, bolstered by a $33.8 million federal income tax refund. Research and development expenses decreased to $28.1 million, reflecting the timing of clinical trials, while general and administrative expenses also saw a reduction.

Enanta’s strategic focus remains on advancing its virology and immunology pipelines, with plans to select a lead candidate for its STAT6 inhibitor program in the second half of 2025 and to expand its immunology portfolio further. The company is well-positioned financially to support its ongoing development programs into fiscal 2028.

Looking ahead, Enanta Pharmaceuticals aims to continue executing its pipeline strategy, exploring partnership opportunities for its RSV assets, and expanding its immunology programs, with a strong commitment to addressing unmet medical needs in viral and inflammatory diseases.